Research / Literature

Research Literature

Here you can search a selected list of NGAL literature relevant for research purposes.

Use the filters to the left to choose from a number of relevant areas or product relation.


Segev G (2013) J Vet Intern Med Sep 10

Acute kidney injury (AKI) is a common and often fatal disorder in dogs. Urine neutrophil gelatinase-associated lipocalin (NGAL)/creatinine ratio is a sensitive and specific biomarker of AKI in ninety-four dogs.

Read more
Source
http://www.ncbi.nlm.nih.gov/pubmed/24020513
Date

Sohotnik R (2013) Am J Physiol Renal Physiol 304(8):F1099-104

Acute kidney injury (AKI) is a common clinical problem that still lacks effective treatment. Phosphodiesterase-5 (PDE5) inhibitors possess anti-apoptotic and anti-oxidant properties, making it a promising therapy for ischemia-reperfusion (I/R) injury of various organs. The present study evaluated the early nephroprotective effects of Tadalafil, a PDE5 inhibitor, in an experimental model of renal I/R.

Read more
Source
http://www.ncbi.nlm.nih.gov/pubmed/23364806
Date

Huber W (2012) J CLI 36:10-12

Sepsis frequently results in acute kidney injury (AKI). Although AKI markedly contributes to mortality in sepsis, its diagnosis is frequently delayed due to limitations of current biomarkers of renal impairment. Neutrophil-gelatinase-associated lipocalin (NGAL) has been demonstrated to be a biomarker of early AKI.

To download as pdf please click here 

Read more
Source
http://www.cli-online.com/featured-articles/early-detection-of-acute-kidney-injury-in-sepsis-how-about-ngal/index.html
Date

Ostermann M (2011) J CLI 35:10-12

Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a promising biomarker for acute kidney injury (AKI). The ultimate goal is for NGAL to enable clinicians to intervene as early as possible and to change the prognosis of AKI.

To download as pdf please click here

Read more
Source
http://www.cli-online.com/index.php?id=3198
Date

Ricci Z (2011) Crit Care 29;15:R160

A study of Fenoldopam efficacy as a pretreatment to avoid AKI on cardiopulmonary bypass pediatric patients using NGAL for definition of AKI...

Read more
Source
http://www.ncbi.nlm.nih.gov/pubmed/21714857
Date